We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, DexCom (DXCM - Free Report) closed at $105.22, marking a +0.34% move from the previous day. This change outpaced the S&P 500's 0.12% gain on the day. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq gained 0.29%.
Heading into today, shares of the medical device company had lost 8.43% over the past month, lagging the Medical sector's loss of 0.98% and the S&P 500's gain of 0.09% in that time.
DexCom will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.34, up 21.43% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $936.02 million, up 21.62% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.23 per share and revenue of $3.54 billion. These totals would mark changes of +41.38% and +21.74%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DexCom is currently a Zacks Rank #3 (Hold).
Investors should also note DexCom's current valuation metrics, including its Forward P/E ratio of 85.19. For comparison, its industry has an average Forward P/E of 27.54, which means DexCom is trading at a premium to the group.
We can also see that DXCM currently has a PEG ratio of 1.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.08 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 111, which puts it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, DexCom (DXCM - Free Report) closed at $105.22, marking a +0.34% move from the previous day. This change outpaced the S&P 500's 0.12% gain on the day. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq gained 0.29%.
Heading into today, shares of the medical device company had lost 8.43% over the past month, lagging the Medical sector's loss of 0.98% and the S&P 500's gain of 0.09% in that time.
DexCom will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.34, up 21.43% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $936.02 million, up 21.62% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.23 per share and revenue of $3.54 billion. These totals would mark changes of +41.38% and +21.74%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DexCom is currently a Zacks Rank #3 (Hold).
Investors should also note DexCom's current valuation metrics, including its Forward P/E ratio of 85.19. For comparison, its industry has an average Forward P/E of 27.54, which means DexCom is trading at a premium to the group.
We can also see that DXCM currently has a PEG ratio of 1.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.08 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 111, which puts it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com.